BEAUTY CARE

Lornamead announces additions to senior management

BY Antoinette Alexander

STAMFORD, Conn. Personal care company Lornamead, whose brands include Finesse and Aqua Net, has announced additions to its senior management team.

David Melagrano has been named vice president of finance for the company’s Stamford-based North and South American operations. Pete Columbia has been named vice president of sales.

Melagrano has spent the majority of his career at Bristol-Myers Squibb, where he held roles in finance, accounting and information technology. He also worked at Cadbury Schweppes in financial planning and analysis and commercial finance supporting new product introductions.

Prior to joining Lornamead, Columbia served as senior vice president of sales and marketing with White Rain Co., where he helped with the relaunch of the White Rain hair care brand. Before that he held sales and marketing positions with Andrew Jergens Co. and Helene Curtis/Unilever.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

BEAUTY CARE

Teva introduces generic Penlac

BY Drew Buono

NORTH WALES, Pa. Teva is introducing its generic to the Sanofi-Aventis anti-fungal medication Penlac nail lacquer.

The brand lost its patent yesterday and was immediately launched by Sandoz and is now being followed by the biggest generic manufacturer Teva.  The generic, Ciclopirox topical solution will be available in an 8 percent strength, in a 6.6 mL bottle.

“Generic pharmaceuticals are playing an increasingly important role in healthcare cost containment,” states John Denman, vice president of sales and marketing at Teva.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

BEAUTY CARE

Hi-Tech announces FDA approval of its generic Penlac

BY Drew Buono

AMITYVILLE, N.Y. Hi-Tech Pharmaceuticals has received final approval from the Food and Drug Administration for its application for the generic version of Dermik Laboratories’ topical nail fungus treatment drug Penlac.

Hi-Tech is a specialty pharmaceutical company that develops, manufactures, and markets brand and generic prescriptions and over-the-counter products for the healthcare industry.

Penlac had sales of $87 million in 2006, according to IMS sales data.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES